FBLG

Fibrobiologics, Inc. (FBLG) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Fibrobiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases, including wound healing (CYWC628), psoriasis (CYPS317), multiple sclerosis (CYMS101), and degenerative disc disease (CybroCell). The company is currently conducting a Phase 1/2 clinical trial for CYWC628 in Australia. On March 30, 2026, the company effected a 1-for-20 reverse stock split.

Key Financial Metrics

Note: The company has no revenue. Operating expenses consist primarily of Research & Development ($1.7M Q2; $4.6M YTD) and General & Administrative ($2.4M Q2; $4.5M YTD).

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $0.5 million for the six months ended June 30, 2026, compared to the same period in 2025, primarily due to a reduction in non-cash expenses related to convertible debt fair value changes and other expenses.
• Capital Raises: The company raised approximately $6.3 million in net cash from financing activities in the first half of 2026, including proceeds from a registered offering, a private placement, the Standby Equity Purchase Agreement (SEPA), and an At-The-Market (ATM) program.
• Reverse Stock Split: A 1-for-20 reverse stock split was executed on March 30, 2026. All share and per-share data in the report have been retroactively adjusted.
• Lease Termination: The company terminated a previous office lease in April 2026, resulting in a one-time loss of approximately $0.1 million but reducing future facility costs.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance of the report. The company has an accumulated deficit of $63.3 million and cash of $3.5 million. Continued operations depend on raising additional capital.
• Nasdaq Delisting Risk: On July 22, 2026, Nasdaq notified the company of a determination to delist its securities due to failure to maintain the $1.00 minimum bid price for 30 consecutive days. Because the company executed a reverse split within the prior year, it is not eligible for a standard 180-day compliance period. The company has appealed this determination.
• Clinical Trial Delays: The Phase 1/2 trial for CYWC628 in Australia is experiencing slower-than-anticipated patient recruitment and enrollment due to protocol eligibility requirements and site limitations. Timelines for data readouts have been extended.
• Manufacturing Challenges: The company faced lower-than-expected yields in manufacturing CYWC628 batches, requiring additional resources to produce sufficient supply for the clinical trial.
• Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties, which has not yet been fully remediated.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.5 million cash balance against the $7.7 million operating cash burn rate for the first half of 2026.
• Delisting Appeal Status: Monitor the outcome of the appeal regarding the Nasdaq delisting determination issued on July 22, 2026.
• Capital Raise Progress: Track the execution of the ATM program and any new equity/debt offerings required to alleviate the "substantial doubt" regarding going concern status.
• Clinical Enrollment: Review updates on patient recruitment rates for the CYWC628 Australian trial and any further timeline extensions.
• Internal Controls: Assess the progress of the remediation plan for the material weakness in financial reporting controls.